-
New study finds a long-neglected key factor in triggering multiple types of cancer
Time of Update: 2022-05-02
▲ The presence of clustered mutations on several representative driver genes is associated with changes in patient survival (Image source: Reference [1])The researchers also identified multiple factors that contribute to such aggregated somatic mutations, such as polybasic substitutions mostly produced by smoking or ultraviolet radiation .
-
Lose fat without losing muscle!
Time of Update: 2022-05-02
References:[1] Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants.
-
"Building" a salt bridge to break the curse of "uncurable", the key target of the king of cancer
Time of Update: 2022-05-02
KRAS gene often 'untargetable'Zhang Yonghui, the corresponding author of the paper, said: "When we develop drugs, we will carefully observe the structure of the target protein and look for compounds that can bind to two key sites .
-
Prenatal Ultrasound Medical Consultation Exploring the "Cloud" Model
Time of Update: 2022-05-02
Recently, the reporter learned from Xiangya Hospital of Central South University that the Hunan Obstetrics Rescue Alliance, led by the obstetrics department of the hospital, officially launched the "5G Remote Prenatal Ultrasound Consultation Platform".
-
Food-induced sexual desire: Chinese scientists "Nature" published an article to reveal the aphrodisiac effect of protein
Time of Update: 2022-05-02
▲ The transition from eating to mating requires Dh31 and Dh31 receptors in the gut (Image source: Reference [1])After entering the brain, Dh31 can activate two types of neurons that express Dh31 receptors, which in turn affect the behavior of flies through two independent neural pathways: one type of neurons inhibits feeding behavior; the other type promotes courtship behavior .
-
Can RNAi, gene therapy, targeted drugs, etc. open a new chapter in lipid-lowering therapy in the post-statin era?
Time of Update: 2022-05-02
In 1987, a large-scale simvastatin survival study (also known as the 4S study) initiated in northern Europe, for the first time confirmed that the application of statins for lipid-lowering therapy can significantly reduce the overall mortality of patients with coronary heart disease .
-
Arkuda develops potential 'first-in-class' therapy for common Alzheimer's disease
Time of Update: 2022-05-02
Retrieved February 10, 2022, from https:// 64m-to-test-drug-frontotemporal-dementia-2023[2] ARKUDA THERAPEUTICS RAISES $64 MILLION SERIES B FINANCING TO ADVANCE PIPELINE OF PROGRAMS TARGETING LYSOSOMAL BIOLOGY TO TREAT NEURODEGENERATIVE DISEASES.
Retrieved February 10, 2022, from https:// -million-series-b-financing-to-advance-pipeline-of-programs-targeting-lysosomal-biology-to-treat-neurodegenerative-diseases/(Original abridged)
-
The State Food and Drug Administration issued the "Guidelines for Compilation of Technical Requirements for Medical Device Products"
Time of Update: 2022-05-02
3. Main contentThe content of product technical requirements generally includes product name, model, specification and its division description (if necessary), performance index, inspection method, term (if applicable) and appendix (if applicable) .
-
siRNA therapy can reduce important risk factors of cardiovascular disease by 98%. Phase 1 clinical results of siRNA therapy are positive
Time of Update: 2022-05-02
Silence Therapeutics announced today that its investigational small interfering RNA (siRNA) therapy SLN360 has achieved positive results in a single-dose escalation Phase 1 clinical trial .
References:[1] Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a).
-
Good news for patients with malignant blood cancer Gamida Cell stem cell transplant product is one step closer to approval
Time of Update: 2022-05-02
S. FDA for the Biologics License Application (BLA) for omidubicel, a stem cell/bone marrow transplant product .
Omidubicel is an allogeneic hematopoietic stem cell (bone marrow) transplant solution for the treatment of blood cancer patients .
-
TOT BIOPHARM-B (1875.HK): A pioneer in the ADC track, the future of differentiated development can be expected
Time of Update: 2022-05-02
Therefore, TOT BIOPHARM did not choose to continue to develop other monoclonal antibody-like drugs, but made a differentiated layout, aiming at the ADC field with higher technical difficulty in R&D and higher threshold for commercial production, becoming the first batch of ADCs in China Innovative drug companies in the field of drug research and development .
-
Sanofi cuts off two early-stage tumor monoclonal antibodies after terminating cooperation with Sangamo cell therapy
Time of Update: 2022-05-02
CompilationAspirinSanofi axed two more cancer-preventing monoclonal antibodies in Phase 1 clinical trials, weeks after terminating a cell therapy partnership with Sangamo .
According to the Federal Register of Clinical Trials, the CD38 antibody study is scheduled to complete data collection for the primary endpoint in September 2023 .
-
BGI's new crown antigen self-test product obtained EU CE access qualification
Time of Update: 2022-05-02
On February 7, BGI announced that the new crown antigen self-test product of its wholly-owned subsidiary BGI EuropeA/S (European Medicine) has recently obtained the EU CE certificate .
details as follows:The COVID-19 self-testing product does not require testing equipment, and features easy operation and quick results.
-
This common thyroid problem does not require immediate treatment for the vast majority of older adults!
Time of Update: 2022-05-02
Subclinical hypothyroidism (hypothyroidism) is one of the most common endocrine diseases in clinical practice, and is mainly characterized by a markedly elevated serum thyrotropin level (usually ≥4. 5
-
Significantly reduces the risk of triple-negative breast cancer recurrence of Keytruda combination Phase 3 clinical results published
Time of Update: 2022-05-02
(MSD) announced that the results of its Phase 3 clinical trial of its blockbuster anti-PD-1 antibody therapy Keytruda in the treatment of high-risk early-stage triple-negative breast cancer (TNBC) were published in the prestigious medical journal The New England Journal of Medicine.
-
Dupixent, which is expected to benefit infants and young children with eczema, has been granted priority review
Time of Update: 2022-05-02
References:[1] FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis.
Retrieved February 10, 2022, from https:// /fda-accepts-dupixent-dupilumab-for-priority-review-in-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-301479373.
-
15 times the incidence rate!
Time of Update: 2022-05-02
The authors believe this is unlikely for two main reasons: a significant increase in diagnosis and surgery had no effect on reducing thyroid cancer mortality; screening diagnoses were largely papillary thyroid cancer—a The histological finding that is prevalent in the general population should be viewed more as a normal variant than a fatal disease .
-
Scientists reveal the effect of tumor exosomes on NK cells in tumor immunotherapy
Time of Update: 2022-05-01
1186/s12943-021-01492-7Recently, researchers from the Faculty of Medicine of the Medical University of Isfahan published a review article entitled "Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy" in the journal Molecular Cancer, on the role of TDEs in tumor induction.
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy.
-
AIDS "cured" after stem cell transplantation, the third case in the world may appear!
Time of Update: 2022-05-01
As a last resort for a cure for the blood tumor, she received a stem cell transplant -- which carries a key mutation in the CCR5 gene that makes the body immune to HIV .
-
Denali macromolecule delivery technology that breaks through the blood-brain barrier is expected to advance to phase 2/3 clinical trials
Time of Update: 2022-05-01
Long-term data from 20 patients showed that after up to 1 year of administration, the drug could continue to reduce the level of disease-related biomarkers in the patient's brain, and initially improve clinical symptoms, with a good safety profile .
